Project Details

Description

Coronavirus disease-2019 (COVID-19) is caused by an infection by
the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which uses the ACE2
receptor and the priming of the proteaseTMPRSS2 to invade human cells. Although the more
important symptoms caused by COVID-19 are pneumonia-related, it also causes other symptoms
affecting multiple organs, such as the digestive tract. Recent studies reported that several cell
types, including some of the intestine, express ACE2 and TMPRSS2, which could explain this
symptomatology [1]. Based on the ACE2 and TMPRSS2 expression, the testis has been classified
as at high risk of being infected by SARS-CoV-2. In fact, some COVID-19 patients suffer scrotum
discomfort, which is commonly associated with viral orchitis [2,3], and unpublished studies reported
reduced testosterone levels in serum from COVID-19 patients [4,5]. However, there are conflicting
reports about the presence of SARS-CoV-2 in semen from COVID-19 patients [3,6,7], arguing that
SARS-CoV-2 may not invade the testis. Nonetheless, COVID-19 may disturb spermatogenesis
indirectly. For instance, due to the hyperinflammatory response of the body, which has been
reported to cause a multiorgan failure as a complication of the disease. Alternatively, the sustained
period of high fever caused by the infection may also impair spermatogenesis [8,9].
AcronymFERRING PHARMACEUTICAL
StatusActive
Effective start/end date1/10/2030/09/21

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.